Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LX
Post# of 721
(Total Views: 209)
Posted On: 09/26/2017 1:50:02 PM
Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) Technology Targets Many Massive Markets
- Technology that improves bio-absorption and bio-availability
- Bioactive compound delivery system with application across a range of drugs
- Revenue streams from out-licensing
The word in culinary circles is that where there is fat, there is flavor. That’s because fats (there are several different kinds) have a matchless ability to absorb and preserve flavors. Fats belong to a class of compounds called lipids, which the human digestive system absorbs remarkably efficiently. This characteristic makes them ideal for pairing with hard to digest remedials and tonics. Taking a leaf, perhaps, from haute cuisine, this is exactly what Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is doing. The innovative biotech has developed a lipid-based system that delivers bioactive compounds more efficiently. The patented proprietary technology, which the company plans to out-license, not only augments bio-absorption and bioavailability but also improves taste, smell and onset of action.
Lexaria’s novel technology, DehydraTECH™, ticks all these boxes by infusing the molecules of organically sourced hemp oil, high in cannabidiol (CBD), inside the molecules of lipids. Lipids seem a natural choice, since the human endocannabinoid system is itself lipid-based. Using them as a vehicle for delivering cannabinoids in curatives results in more absorption, less waste and, just as importantly, fewer side effects (http://nnw.fm/7Yuym). With DehydraTECH, a little hemp oil goes a long way, improving the healthful benefits and, of course, saving money.
Lexaria has already applied this innovative delivery technology to its product line, which consists of three distinct brands: ViPova, Lexaria Energy and TurboCBD. ViPova is a delicious Chinese black tea from the province of Yunnan, made from hemp oil-infused within dried evaporated non-fat milk. Introduced in January 2015, the tea is available in a host of varieties and flavors. The Lexaria Energy line is meant for those with busy, active lifestyles. Under this brand, the company has launched a hemp oil-infused protein bar called the Lexaria Energy Bar, which, as its name suggests, provides reserves of energy to boost stamina. In addition, there is Lexaria’s TurboCBD, a brand of technologically enhanced, high absorption hemp oil capsules that came to market in March 2017. TurboCBD’s cannabinoid content is fortified with high-quality American ginseng and ginkgo biloba for support of enhanced focus and memory, along with reduced stress and fatigue.
However, as will be apparent, the DehydraTECH process is not restricted to delivering cannabinoids alone. It can be used to improve the delivery of other cannabinoids (apart from CBD) as well as vitamins, non-steroid anti-inflammatory drugs (NSAIDs) and nicotine. This puts Lexaria in the enviable position of being a natural partner to cannabinoid biotech companies and an enabler rather than a competitor. Moreover, at present, Lexaria is the only company in the world that has been awarded a patent for the improved delivery (oral or ingestible, including pills) of all non-psychoactive cannabinoids. Patents have been awarded in the U.S. and Australia and are pending in 40 more countries. This puts the company in the unusually advantageous position of owning proprietary technology that can deliver a vast range of non-psychoactive cannabinoid-based drugs.
Lexaria’s partnership potential is worth taking notice of as landmark M&A deals continue to shape Big Pharma (http://nnw.fm/sJ1Qw). Its delivery technology has applications in some giant markets. As the referenced article notes, “According to biotech analysis firm EvaluatePharma, the global market for NSAIDs was valued at $11.4 billion in 2014. Meanwhile, the global market for vitamins is on course to reach $9.3 billion by 2020, the market for alternative nicotine delivery technologies is at an all-time high following recent FDA proposals, and consumer sales of cannabinoids are expected to reach $2.1 billion by 2020. All told, the market potential for Lexaria’s flagship platform could be huge.”
For more information, visit the company’s website at www.LexariaEnergy.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Technology that improves bio-absorption and bio-availability
- Bioactive compound delivery system with application across a range of drugs
- Revenue streams from out-licensing
The word in culinary circles is that where there is fat, there is flavor. That’s because fats (there are several different kinds) have a matchless ability to absorb and preserve flavors. Fats belong to a class of compounds called lipids, which the human digestive system absorbs remarkably efficiently. This characteristic makes them ideal for pairing with hard to digest remedials and tonics. Taking a leaf, perhaps, from haute cuisine, this is exactly what Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is doing. The innovative biotech has developed a lipid-based system that delivers bioactive compounds more efficiently. The patented proprietary technology, which the company plans to out-license, not only augments bio-absorption and bioavailability but also improves taste, smell and onset of action.
Lexaria’s novel technology, DehydraTECH™, ticks all these boxes by infusing the molecules of organically sourced hemp oil, high in cannabidiol (CBD), inside the molecules of lipids. Lipids seem a natural choice, since the human endocannabinoid system is itself lipid-based. Using them as a vehicle for delivering cannabinoids in curatives results in more absorption, less waste and, just as importantly, fewer side effects (http://nnw.fm/7Yuym). With DehydraTECH, a little hemp oil goes a long way, improving the healthful benefits and, of course, saving money.
Lexaria has already applied this innovative delivery technology to its product line, which consists of three distinct brands: ViPova, Lexaria Energy and TurboCBD. ViPova is a delicious Chinese black tea from the province of Yunnan, made from hemp oil-infused within dried evaporated non-fat milk. Introduced in January 2015, the tea is available in a host of varieties and flavors. The Lexaria Energy line is meant for those with busy, active lifestyles. Under this brand, the company has launched a hemp oil-infused protein bar called the Lexaria Energy Bar, which, as its name suggests, provides reserves of energy to boost stamina. In addition, there is Lexaria’s TurboCBD, a brand of technologically enhanced, high absorption hemp oil capsules that came to market in March 2017. TurboCBD’s cannabinoid content is fortified with high-quality American ginseng and ginkgo biloba for support of enhanced focus and memory, along with reduced stress and fatigue.
However, as will be apparent, the DehydraTECH process is not restricted to delivering cannabinoids alone. It can be used to improve the delivery of other cannabinoids (apart from CBD) as well as vitamins, non-steroid anti-inflammatory drugs (NSAIDs) and nicotine. This puts Lexaria in the enviable position of being a natural partner to cannabinoid biotech companies and an enabler rather than a competitor. Moreover, at present, Lexaria is the only company in the world that has been awarded a patent for the improved delivery (oral or ingestible, including pills) of all non-psychoactive cannabinoids. Patents have been awarded in the U.S. and Australia and are pending in 40 more countries. This puts the company in the unusually advantageous position of owning proprietary technology that can deliver a vast range of non-psychoactive cannabinoid-based drugs.
Lexaria’s partnership potential is worth taking notice of as landmark M&A deals continue to shape Big Pharma (http://nnw.fm/sJ1Qw). Its delivery technology has applications in some giant markets. As the referenced article notes, “According to biotech analysis firm EvaluatePharma, the global market for NSAIDs was valued at $11.4 billion in 2014. Meanwhile, the global market for vitamins is on course to reach $9.3 billion by 2020, the market for alternative nicotine delivery technologies is at an all-time high following recent FDA proposals, and consumer sales of cannabinoids are expected to reach $2.1 billion by 2020. All told, the market potential for Lexaria’s flagship platform could be huge.”
For more information, visit the company’s website at www.LexariaEnergy.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼